CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,038 from $1,029 and keeps a Buy rating on the shares. The firm is updating its ...
Evaluate the expected performance of Lilly (LLY) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...
Zacks.com on MSN2d
Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...
We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback